- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
InspireMD's CGuard System Featured at Cardiology Congress
InspireMD announced the endovascular interventional procedure which features the CGuard EPS was recorded and presented at this year’s SOLACI CACI Congress of Cardiology.
InspireMD (NYSEMKT:NSPR) announced the endovascular interventional procedure which features the CGuard EPS was recorded and presented at this year’s SOLACI CACI Congress of Cardiology.
As quoted in the press release:
The case, entitled “Self Expanding Stent to Avoid Distal Embolization: Carotid InspireMD Stent Case presentation,” was displayed to the entire congress.
SOLACI CACI ’17 is the official annual meeting of the Latin American Society of Interventional Cardiology and the Argentinian School of Interventional Cardiologists, and is the largest meeting of cardiologists and interventional cardiologists in Latin America. SOLACI CACI ’17 is taking place from August 2-4, 2017.
Dr. Anibal Damonte, commented, “The CGuard™ EPS performed exceedingly well in a challenging case. The MicroNet™ technology enables us to treat carotid artery disease safely in cases that would not have been possible with conventional carotid stents.”
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.